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Background: In heart failure (HF), concentrations of the interleukin-1 receptor family member ST2 predict prognosis. We recently found beta 
blockers (BB) may affect ST2 concentrations. It remains unclear if ST2 concentrations identify benefit of BB.
methods: 151 subjects with HF due to left ventricular systolic dysfunction (LVSD) were examined; >98% were taking BB at enrollment. Subjects 
had a measurement of soluble (s)ST2 (Presage ST2, Critical Diagnostics) and followed over 10 months. Cardiovascular (CV) events were examined 
as a function of sST2 status (“low” ≤ 35 vs. “high” > 35 ng/mL) and final achieved BB dose (“high” ≥50 vs. “low” <50 mg daily equivalent dose of 
metoprolol succinate).
results: Patients with low sST2 that achieved high-dose BB had the lowest CV event rate at 0.53 events (Figure A, p=0.001), and best event-free 
survival (Figure B, p=0.003). Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes. Those with high sST2/low-
dose BB had the highest CV event rate and worst event-free survival. Compared to low sST2/high-dose BB, those with high sST2 achieving only low-
dose BB had an odds ratio (OR) of 6.77 (p<0.001) for a CV event. Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate 
ORs for CV events approximately 2 times higher (p=0.18 and 0.02). Similar findings were present for HF hospitalization and CV death.
conclusion: In HF due to LVSD, sST2 measurement identifies chronic HF patients who particularly benefit from high-dose BB therapy.
 
